Related Experiment Videos
Recent observations with beta-adrenoceptor blockade. Beneficial effects in hypertension and heart failure
R R Ruffolo1, G Z Feuerstein, E H Ohlstein
1Division of Pharmacological Sciences, SmithKline Beecham Pharmaceuticals, King of Prussia, PA 19406-0939, USA.
Insights
Carvedilol, a beta-blocker, effectively treats hypertension and heart failure by lowering blood pressure and protecting the heart. Its antioxidant properties further enhance its therapeutic benefits in cardiovascular conditions.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Carvedilol is a third-generation vasodilating beta-blocker.
- Initially approved for hypertension, it lowers blood pressure without reflex tachycardia and preserves renal function.
Purpose of the Study:
- To review the multifaceted therapeutic properties of carvedilol.
- To highlight its efficacy in congestive heart failure and its antioxidant mechanisms.
Main Methods:
- Literature review of carvedilol's pharmacological actions.
- Analysis of clinical outcomes in hypertension and heart failure patients.
Main Results:
- Carvedilol reduces morbidity and mortality in congestive heart failure patients.
- It exhibits both beta-blockade and alpha 1-adrenoceptor blockade, leading to vasodilation.
- Carvedilol and its metabolites possess potent antioxidant properties, inhibiting myocardial damage.
Conclusions:
- Carvedilol offers a novel therapeutic approach for hypertension and heart failure.
- Its combined vasodilating, beta-blocking, and antioxidant effects provide comprehensive cardiovascular protection.
Abstract:
Carvedilol is a third-generation vasodilating beta-blocker initially approved for the treatment of hypertension. It lowers systemic arterial blood pressure without causing reflex tachycardia and preserves renal function. More recently, carvedilol has been shown to reduce morbidity and mortality in patients with congestive heart failure. This reduction may occur in part via beta-blockade and alpha 1-adrenoceptor blockade, the latter resulting in vasodilation. Importantly, carvedilol and several of its metabolites are potent antioxidants that may inhibit the oxidation of norepinephrine and the subsequent formation of toxic intermediates, such as reactive free radicals in the myocardium. As a result, carvedilol inhibits the expression of certain genes involved in myocardial damage, such as intracellular adhesion molecule-1, free-radical-induced activation of transcription factors, and programmed cell death or apoptosis. In this respect, carvedilol represents a new therapy for the treatment of hypertension and congestive heart failure and combines, in one molecule, a number of potentially beneficial properties.